Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Fernandez

Neurology Hattiesburg, MS Medical Doctor

NPI 1144230491 CMS profile 278953

1 Lincoln Pkwy Ste 302, Hattiesburg, MS 39402

Open in the dashboard

General payments

$20,445

1,137 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Fernandez of Hattiesburg, MS is reported in the CMS Open Payments database as having received $20,445 across 1,137 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,164 200
2024 General $3,935 209
2023 General $3,395 193
2022 General $3,710 194
2021 General $2,168 137
2020 General $1,145 79
2019 General $1,928 125

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Fernandez
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Jose Fernandez were reported at $4,164. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Jose Fernandez Neurology median Middle half National median
2019 $1,928 $474 $118–$2,177 $163
2020 $1,145 $367 $82–$2,309 $114
2021 $2,168 $438 $104–$2,547 $132
2022 $3,710 $442 $103–$2,388 $149
2023 $3,395 $464 $119–$2,312 $160
2024 $3,935 $468 $119–$2,323 $164
2025 $4,164 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,082 141 payments
  2. ACADIA Pharmaceuticals Inc $1,271 68 payments
  3. Teva Pharmaceuticals USA, Inc. $1,018 62 payments
  4. Eisai Inc. $1,006 50 payments
  5. Alexion Pharmaceuticals, Inc. $827 38 payments
  6. Argenx US, Inc. $760 31 payments
  7. SK Life Science, Inc. $735 29 payments
  8. Neurocrine Biosciences, Inc. $703 34 payments
  9. Novartis Pharmaceuticals Corporation $665 37 payments
  10. Pfizer Inc. $661 55 payments
  11. Other $10,716 592 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $20,012 1,127 payments
  2. Travel and Lodging $213 1 payment
  3. Education $119 4 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $101 5 payments
Products named General payments · program years 2019–2025
  1. QULIPTA $984 74 payments
  2. NUPLAZID $848 40 payments
  3. ULTOMIRIS $607 23 payments
  4. UBRELVY $587 44 payments
  5. INGREZZA $577 27 payments
  6. NEUROSTAR TMS THERAPY SYSTEM $557 2 payments
  7. ZEPOSIA $554 31 payments
  8. Leqembi $540 26 payments
  9. NURTEC ODT $539 44 payments
  10. APTIOM $530 35 payments
  11. Other $15,011 879 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

4,684

Median for Neurology: 833

Drug cost

$817,083

Median for Neurology: $202,670

Branded share of claims

14.6%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 15 $182,465
Aptiom Eslicarbazepine Acetate Brand 99 $132,744
Avonex (4 Pack) Interferon Beta-1a Brand 16 $130,132
Kesimpta Pen Ofatumumab Brand 12 $102,730
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 12 $57,290
Fycompa Perampanel Brand 37 $45,937
Glatopa Glatiramer Acetate Brand 14 $27,300
Xcopri Cenobamate Brand 23 $25,746
Oxcarbazepine Generic 415 $12,717
Levetiracetam Generic 489 $10,807

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$412,255

Of which drugs: $293,139

Medicare patients

614

Average age 73

Services billed

68,182

368 women, 246 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 44%
Depression 39%
Diabetes 37%
Chronic kidney disease 30%
COPD 24%
Alzheimer's or dementia 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, lecanemab-irmb, 1 mg J0174 Office 25 55,300 $58,021
Injection, denosumab, 1 mg J0897 Office 27 1,680 $34,727
Injection, gadopiclenol, 1 ml A9573 Office 33 311 $1,828

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 48 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ULTOMIRIS
$243 — —
VYVGART Hytrulo
$241 — —
QULIPTA
$236 — —
BOTOX
$219 — —
Leqembi
$216 — 55,300

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 48 with Patron

Records

1,137 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record